ReviewBiomedicines2026
Allergen Immunotherapy and Possible Clinical Remission: Toward a Disease-Modifying Paradigm in Allergic Disorders.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sublingual allergen immunotherapy: evidence from randomized trials, real-world studies and meta-analyses.Frontiers in allergy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergen immunotherapy (AIT) represents the only disease-modifying treatment currently available for IgE-mediated allergic diseases. Traditionally employed to alleviate symptoms and reduce pharmacological dependence, AIT is now being reconsidered within a broader and more ambitious therapeutic framework: the induction of long-term clinical remission. In the field of allergic diseases, the concept of disease control has recently been integrated with that of clinical remission. This review discusses the evolving concept of remission in allergic disorders, particularly allergic rhinitis and allergic asthma, in patients treated with AIT. Starting from the definition of clinical remission, this review aims to analyze the evidence supporting this concept and explore potential tools for clinical application in allergic patients treated with AIT, the only causal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.